Aug 2026
Alzheimers disease blood biomarkers reveal proteomic modules of disease progression
Routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.
R. R. Butler, M. P. Brown, A. Weber et al.
· medRxiv · 0 citations